Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington s Disease Therapeutics Conference
April 27, 2021 03:00 ET | Source: AFFiRiS AG AFFiRiS AG Vienna, AUSTRIA
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology
Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance
Results set the ground for AFFiRiS’ potential first-in-class antibody-based systemic therapeutic modalities targeting mtHTT directly
VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of